Premium accounts now available! Sign up and create a premium account. Read more Close

Advertisement

Image

Spatiotemporal Control of Genetic and Epigenetic Editing through Covalent Tethering of CRISPR Nanoparticles to Zwitterionic Microgels

Preprint Created on 22 Sep 2026 bioRxiv

CRISPR gene editing offers unprecedented genomic and transcriptomic control, positioning it as a powerful tool for cell therapies. Non-viral CRISPR delivery avoids the immunogenicity, genomic integration, and packaging limits of viral vectors, but local or systemic injections of non-viral nanoparticles suffers from transient action and poor biodistribution. Alternatively, biomaterial-based delivery improves nanoparticle localization and sustains delivery, yet current approaches rely on non-specific adsorption of nanoparticles to scaffolds, risking aggregation, destabilization, and unreliable release kinetics. This work establishes a novel strategy to covalently tether nanoparticles to biomaterial substrates through SnoopTag and SpyTag bioconjugation systems for spatiotemporal control of non-viral CRISPR delivery. The RALA cell-penetrating peptide, an efficient and low-cytotoxicity CRISPR delivery system, was functionalized with SnoopTag without altering nanoparticle formation or transfection capacity. SnoopTag-functionalized nanoparticles were then covalently tethered to SpyTag-decorated zwitterionic microgels via a SnoopCatcher-SpyCatcher fusion protein. This platform achieves sustained RALA-mRNA nanoparticle delivery and prolonged CRISPR activation in human mesenchymal stem cells seeded within CRISPR-loaded microgel scaffolds. This work establishes a defined biorthogonal conjugation system that tethers non-viral nanoparticles to biomaterial platforms for sustained and localized CRISPR gene editing.

Graham, J. P., Wheeler, E. E., Leach, K. J., Gonzalez-Fernandez, T.

Advertisement

Stats

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 1
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement